Medtronic says FDA needs stent data

(Reuters) - The company also still expects FDA approval of the
so-called Endeavor stent in the United States later this year.




Medtronic shares closed down $1.08, or 2.1 percent, to
$51.55 on the New York Stock Exchange.


Read more at Reuters.com Government Filings News